PHI, Inc. (PHII) Touches $1.35 Low on Mar, 24; ChemoCentryx, Inc. (CCXI) Had 4 Bullish Analysts


Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since November 12, 2018 according to SRatingsIntel. Leerink Swann initiated the shares of CCXI in report on Thursday, February 14 with “Buy” rating. As per Tuesday, March 12, the company rating was maintained by H.C. Wainwright. The company was maintained on Monday, November 12 by Canaccord Genuity. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:

12/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $23 Maintain
14/02/2019 Broker: Leerink Swann Rating: Buy Initiate
11/02/2019 Broker: PiperJaffray Rating: Overweight New Target: $20 Initiates Coverage On
12/11/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain

The stock of PHI, Inc. (NASDAQ:PHII) reached all time low today, Mar, 24 and still has $1.30 target or 4.00% below today’s $1.35 share price. This indicates more downside for the $13.36M company. This technical setup was reported by If the $1.30 PT is reached, the company will be worth $534,560 less. The stock decreased 3.57% or $0.05 during the last trading session, reaching $1.35. About 87,271 shares traded or 134.78% up from the average. PHI, Inc. (NASDAQ:PHII) has declined 67.28% since March 24, 2018 and is downtrending. It has underperformed by 71.65% the S&P500.

The stock increased 3.90% or $0.41 during the last trading session, reaching $10.91. About 505,816 shares traded or 39.39% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 24, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

Since October 16, 2018, it had 0 buys, and 8 insider sales for $87.64 million activity. On Tuesday, January 22 KANAYA SUSAN M sold $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) or 37,893 shares. 7,211 shares valued at $86,554 were sold by Schall Thomas J. on Wednesday, November 7. Another trade for 13,203 shares valued at $158,790 was made by Cappel Markus J. on Monday, January 7. $85.85 million worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by GLAXOSMITHKLINE PLC.

More important recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also published article titled: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq”, published: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) was released by: and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 26, 2019.

Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It dropped, as 7 investors sold ChemoCentryx, Inc. shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mgmt holds 37,000 shares or 0% of its portfolio. Federated Inc Pa reported 65,761 shares or 0% of all its holdings. Northern Trust Corp reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Citigroup Inc invested in 4,073 shares. California State Teachers Retirement reported 35,245 shares. Blackrock Inc holds 2.73M shares. 126,200 were accumulated by Spark Inv Mgmt Ltd Llc. Ameriprise Fincl invested in 0% or 264,496 shares. Bb&T Ltd holds 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 114,827 shares. American Interest Grp Incorporated Inc reported 14,790 shares. Jpmorgan Chase And holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 5,738 shares. The Massachusetts-based Fernwood Inv Lc has invested 0.07% in ChemoCentryx, Inc. (NASDAQ:CCXI). Morgan Stanley holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 39,571 shares. Los Angeles Cap Mgmt And Equity Research accumulated 19,032 shares. Franklin Res reported 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI).

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $573.53 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Investors sentiment increased to 1.14 in 2018 Q4. Its up 0.23, from 0.91 in 2018Q3. It increased, as 5 investors sold PHI, Inc. shares while 17 reduced holdings. 12 funds opened positions while 13 raised stakes. 6.30 million shares or 17.68% less from 7.66 million shares in 2018Q3 were reported. Blackrock Inc reported 825,869 shares. Invesco Limited has invested 0% of its portfolio in PHI, Inc. (NASDAQ:PHII). Royal Bank & Trust Of Canada reported 0% in PHI, Inc. (NASDAQ:PHII). Rmb Ltd Liability Company accumulated 0% or 18,369 shares. Dimensional Fund Advsrs Lp, a Texas-based fund reported 1.06M shares. Amer International holds 7,716 shares. Deutsche Savings Bank Ag accumulated 310,929 shares. Bnp Paribas Arbitrage Sa accumulated 607 shares. Savings Bank Of America Corporation De invested in 0% or 8,531 shares. Prescott Gru Capital Management Lc reported 315,000 shares. Wells Fargo And Communication Mn holds 16,917 shares. Rhumbline Advisers invested 0% in PHI, Inc. (NASDAQ:PHII). Legal And General Grp Public Ltd Liability Co holds 1,800 shares or 0% of its portfolio. Jpmorgan Chase & holds 9,070 shares. California Public Employees Retirement Sys reported 44,556 shares.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *